Joseph Kissil, PhD, is an associate professor at The Scripps Research Institute.
Scientists from the Florida campus of The Scripps Research Institute (TSRI) have identified a new drug candidate for an inherited form of cancer with no known cure.
The new study showed the drug candidate—known as FRAX97—slowed the proliferation and progression of tumor cells in animal models of Neurofibromatosis type 2. This inherited type of cancer, caused by mutations in the anti-tumor gene NF2, leads to tumors of the auditory nerve that connects the inner ear to the brain.
The new compound, originally developed to treat neurodegenerative disease, targets a protein family known as p21-activated kinases or PAKs. These kinases (enzymes that add a phosphate group to other proteins and change their function) play a critical role in the development of Neurofibromatosis type 2. PAK1 has also been implicated in the growth of breast and lung cancers.
“Our study shows that if we inhibit these kinases we can counter the formation of tumors in this brain disease,” said Joseph Kissil, a TSRI associate professor who led the study.
In the new study, published in the October 4, 2013 issue of The Journal of Biological Chemistry, Kissil and his colleagues showed that the inhibitor slows down progression of Neurofibromatosis type 2 in animal models and reduces more than 80 percent of PAK1 activity.
Kissil notes a key challenge in developing drug candidates is finding potential agents that are both potent and highly selective for their targets—limiting its action to the desired arena and reducing unwanted side effects.
“This inhibitor turned out to be both potent and highly selective,” he said. “The real question is why. We were able to show that it works through a unique mechanism.”
The Latest Bing News on:
Neurofibromatosis
- Father whose incurable condition causes tumours on his nerves reveals warning sign everyone should knowon May 11, 2022 at 7:16 am
Somerset account manager Mike Bird, 37, was diagnosed with neurofibromatosis type 1 (NF1) as a baby after a seizure alerted doctors ...
- Jason Colodne and Colbeck Capital Sponsor Children’s Tumor Foundation’s 2022 World NF Awareness Day Live Eventon May 11, 2022 at 6:09 am
CTF is dedicated to fighting for a cure, education, and advocacy of the genetic disorder neurofibromatosis, NF. May is NF Awareness Month and May 17 is dedicated as World NF Day, a time that the ...
- Dad and kids live with genetic condition that causes tumours to grow on nerves and skinon May 11, 2022 at 1:47 am
Mike Bird, 37, was found to have neurofibromatosis type 1 (NF1) as a baby, after a seizure alerted doctors to a gene mutation that resulted in his diagnosis. Determined to raise awareness of the ...
- Dad whose incurable genetic condition causes tumours to grow on nerves and skin and affects two of his children fears no one has heard of iton May 10, 2022 at 11:00 pm
Somerset account manager Mike Bird, 37, was diagnosed with neurofibromatosis type 1 (NF1) as a baby after a seizure alerted doctors ...
- This Runner Clocks Miles to Relieve Stress and Raise Money for Genetic Disorder Researchon May 10, 2022 at 9:50 am
I also run to raise money to find a cure for neurofibromatosis (NF), which is a genetic disorder I’ve had since birth. My neurofibromatosis (NF) journey began at birth. I was born with a tumor behind ...
- Neurofibromatosison May 5, 2022 at 5:20 am
There are three types of neurofibromatosis: neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2) and schwannomatosis. NF1 is usually diagnosed in childhood, while NF2 and schwannomatosis are ...
- Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and overon May 4, 2022 at 10:55 pm
3.1 Type 1 neurofibromatosis (NF1) is a rare genetic disease in which symptoms arise in early childhood and are lifelong. It is caused by mutations in the NF1 tumour suppressor gene. Because the ...
- Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and overon May 4, 2022 at 10:53 pm
There is a simple discount patient access scheme for selumetinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact market.accessuk ...
- May is NF (Neurofibromatosis) Awareness Month, Announces Children's Tumor Foundationon May 1, 2022 at 4:00 am
NF, short for neurofibromatosis, is a group of genetic disorders that causes tumors to grow on nerves throughout the body. NF affects 2.5 million people around the world, but many have not heard of ...
- Neurofibromatosis Type 1 Market 2022 Research, Size, Share Analysis by Manufacturers, Regions, Type and Application to 2028on April 27, 2022 at 7:47 pm
“Neurofibromatosis Type 1 Market” Report provides detail analysis on major industry drivers, restraints, and their effect on market growth during the estimate period. This report mainly ...
The Latest Google Headlines on:
Neurofibromatosis
The Latest Bing News on:
Inherited Cancer
- Study modeling tumor evolution reveals a central tradeoff that could be exploited for cancer treatmenton May 11, 2022 at 2:59 pm
who tend to develop cancer due to inherited mutations in their TP53 genes." Taha Merghoub, Ludwig MSK investigator Reviewing the literature on TP53 mutations detected in precancerous tissues, the ...
- How to monitor your skin for melanoma and other skin canceron May 11, 2022 at 2:07 pm
May is Skin Cancer Awareness Month, and according to the CDC, skin cancer is the most common form of cancer in the United States. It is important to know your risks and how to monitor your skin ...
- Ludwig MSK study modeling tumor evolution reveals a vulnerability for cancer prevention and therapyon May 11, 2022 at 12:28 pm
who tend to develop cancer due to inherited mutations in their TP53 genes.” Reviewing the literature on TP53 mutations detected in precancerous tissues, the researchers found the same hotspots as ...
- Study modeling tumor evolution reveals a vulnerability for cancer prevention and therapyon May 11, 2022 at 9:26 am
Though the mutations accumulated by cancer cells occur more or less randomly, certain regions of genes essential to cancer growth appear to be more frequently mutated than others in established tumors ...
- Genetic Testing Market Size Worth USD 30.1 Billion by 2027 at 10.3% CAGR - Report by Market Research Future (MRFR)on May 11, 2022 at 9:17 am
Genetic Testing Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), "Genetic Testing Market Information by Type, Method, ...
- Insights Into Genetic ‘Hotspots’ Could Produce New Cancer Treatment Strategieson May 11, 2022 at 8:31 am
Researchers know that hotspots can contribute to cancer development and growth. The TP53 gene, for example, makes a protein critical for removing cells with genetic mistakes that could lead to cancer.
- Making genetic testing more inclusiveon May 9, 2022 at 11:00 pm
For the past 30 years, Myriad Genetics has been involved in genetic testing to help women determine their risk of breast cancer. Typically, about 5% of women test positive for a high-risk genetic ...
- Common genetic mutation allows cancer cells to gain extra chromosomes that help them surviveon May 9, 2022 at 7:31 am
Scientists have found a genetic mutation that results in cancer cells being able to tolerate having an abnormal number of chromosomes—a condition which normally kills cells—allowing them to ...
- Genetic Changes in Patients Who Progress to Esophageal Cancer Identifiedon May 8, 2022 at 10:26 am
To address this, Hutch researchers set up the Seattle Barrett's Esophagus Study in the early 1980s to learn more about BE, how it progresses, and find any genetic characteristics that flag patients at ...
- For Mother’s Day, I’m Hoping to Help Prevent Hereditary Canceron May 6, 2022 at 6:58 am
With Mother’s Day upon us, I’m advocating for better genetic cancer screening so that no more children are motherless on this day.
